BioSpace News Archive

The National Advertising Division (NAD) recommended that PRN Physician Recommended Nutraceuticals discontinue certain challenged product and ingredient claims for its nuretin medical food, following a challenge by the Council for Responsible Nutrition (“CRN”).

Campylobacter is a major foodborne pathogen in many parts of the world and its ensuing illness, campylobacteriosis, is the most frequently reported bacterial foodborne illness in Canada, outnumbering the reported cases of Listeria, Salmonella, and Shiga-toxigenic Escherichia coli infections combined.

Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed entering into discussions with Puration, Inc. (USOTC: PURA) (“PURA”) regarding PURA’s possible acquisition of KALY’s CBD confection assets.

CrossBay Medical, Inc., a health technology company focused on humanizing the delivery of women’s healthcare, has announced the launch of a new website, introducing its CrossGlide™ technology platform.

Encore Life, the only practitioner-exclusive professional grade CBD manufacturer, and WholeScripts, powered by XYMOGEN, the fastest growing supplier of nutritional supplements, have signed a partnership agreement naming Encore Life as the premier CBD product line offered via WholeScripts’ sales channels.

Soin Neuroscience, a biotechnology company based in Dayton, OH, has developed a new spinal cord stimulation device to treat chronic pain.

Hansa Biopharma will publish its Year-End report 2019 at 8:00 a.m. CET on February 6, 2020.

DNA Genotek Inc. announced that the U.S. Food and Drug Administration has granted a general use 510 clearance for its Oragene®•Dx family of products.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today stated that the previously announced abstract for a poster to be presented at the 2020 Gastrointestinal Cancers Symposium sponsored by ASCO in San Francisco, has been published

Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced the presentation of results from an ex vivo study of the Company’s proprietary cystic fibrosis transmembrane conductance regulato